JP2009537563A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537563A5
JP2009537563A5 JP2009511209A JP2009511209A JP2009537563A5 JP 2009537563 A5 JP2009537563 A5 JP 2009537563A5 JP 2009511209 A JP2009511209 A JP 2009511209A JP 2009511209 A JP2009511209 A JP 2009511209A JP 2009537563 A5 JP2009537563 A5 JP 2009537563A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
administered
amount
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068982 external-priority patent/WO2007134326A2/en
Publication of JP2009537563A publication Critical patent/JP2009537563A/ja
Publication of JP2009537563A5 publication Critical patent/JP2009537563A5/ja
Pending legal-status Critical Current

Links

JP2009511209A 2006-05-15 2007-05-15 Taci融合分子を使用する自己免疫疾患を治療するための方法 Pending JP2009537563A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74727006P 2006-05-15 2006-05-15
PCT/US2007/068982 WO2007134326A2 (en) 2006-05-15 2007-05-15 Methods for treating autoimmune diseases using a taci-ig fusion molecule

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013000231A Division JP2013100313A (ja) 2006-05-15 2013-01-04 Taci融合分子を使用する自己免疫疾患を治療するための方法

Publications (2)

Publication Number Publication Date
JP2009537563A JP2009537563A (ja) 2009-10-29
JP2009537563A5 true JP2009537563A5 (enExample) 2010-07-01

Family

ID=38694783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009511209A Pending JP2009537563A (ja) 2006-05-15 2007-05-15 Taci融合分子を使用する自己免疫疾患を治療するための方法
JP2013000231A Pending JP2013100313A (ja) 2006-05-15 2013-01-04 Taci融合分子を使用する自己免疫疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013000231A Pending JP2013100313A (ja) 2006-05-15 2013-01-04 Taci融合分子を使用する自己免疫疾患を治療するための方法

Country Status (17)

Country Link
US (1) US8784812B2 (enExample)
EP (1) EP2035028A2 (enExample)
JP (2) JP2009537563A (enExample)
KR (1) KR20090016707A (enExample)
CN (1) CN101489573B (enExample)
AR (1) AR060935A1 (enExample)
AU (1) AU2007249223B2 (enExample)
BR (1) BRPI0711823A2 (enExample)
CA (1) CA2651791A1 (enExample)
EA (1) EA015342B1 (enExample)
EC (1) ECSP088982A (enExample)
IL (1) IL195243A0 (enExample)
MX (1) MX2008014365A (enExample)
NZ (1) NZ572373A (enExample)
UA (1) UA98462C2 (enExample)
WO (1) WO2007134326A2 (enExample)
ZA (1) ZA200809202B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852591B2 (en) 2007-03-27 2014-10-07 Zymogenetics, Inc. Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
PT2167038T (pt) * 2007-06-13 2018-06-01 Zymogenetics Inc Utilização de proteína de fusão taci-ig, tal como atacicept para o fabrico de um medicamento para tratar lúpus eritematoso
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
WO2011109280A1 (en) * 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN103458776B (zh) * 2010-11-26 2016-06-08 血液公司 用于确定疾病活动的系统
US20170247462A1 (en) 2014-07-03 2017-08-31 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
JP2024514077A (ja) * 2021-03-31 2024-03-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 切断したtaciポリペプチド及びその融合タンパク質並びに使用
IL308336A (en) * 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
US20240018212A1 (en) * 2021-09-30 2024-01-18 RemeGen Co., Ltd Method for treating sjogren's syndrome using taci-fc fusion protein
WO2024159715A1 (zh) * 2023-01-31 2024-08-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗IgG4相关性疾病的方法
TW202525840A (zh) * 2023-09-28 2025-07-01 大陸商榮昌生物製藥(煙臺)股份有限公司 用TACI-Fc融合蛋白治療抗體介導性排斥反應的方法

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DK368882A (da) * 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) * 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) * 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) * 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) * 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) * 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) * 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) * 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ES2092468T3 (es) * 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) * 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162222A (en) * 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
JPH05504479A (ja) 1990-02-09 1993-07-15 ザ ソーク インスティテュート フォア バイオロジカル スタディーズ レチノイドレセプター組成物および方法
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5650550A (en) * 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) * 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
AU706401B2 (en) 1994-12-15 1999-06-17 Yeda Research And Development Co. Ltd. Modulators of the function of FAS/APO1 receptors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
CA2237039A1 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
ATE254135T1 (de) 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US5736383A (en) * 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
EP0991759A1 (en) 1997-06-06 2000-04-12 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
HUP0004034A3 (en) 1997-09-12 2002-08-28 Apotech R & D Sa Kay - a novel immune system protein
AU759717B2 (en) 1997-09-12 2003-04-17 Apoxis Sa April- a novel protein with growth effects
DE19831987A1 (de) 1998-07-16 2000-01-20 Bayer Ag Diphenylimidazoline
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
AU781577B2 (en) 1998-12-30 2005-06-02 Lakewood-Amedex, Inc. Therapeutic phosphodiesterase inhibitors
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CN1342202A (zh) 1999-01-07 2002-03-27 津莫吉尼蒂克斯公司 可溶性受体br43×2和应用方法
ES2204528T3 (es) 1999-01-25 2004-05-01 Biogen, Inc. Baff, sus inhibidores y su uso en la modulacion de la respuesta de las celulas b.
AU777536B2 (en) 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
DK1180159T3 (da) * 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
JP4787439B2 (ja) 1999-08-17 2011-10-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 免疫調節因子であるbaffレセプター(bcma)
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
DK1297013T3 (da) 2000-04-27 2006-12-27 Biogen Idec Inc Anvendelse af TACI som antitumormiddel
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU8009601A (en) 2000-08-11 2002-02-25 Kirin Brewery Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
AU2002230659A1 (en) * 2000-11-07 2002-05-21 Zymogenetics Inc. Human tumor necrosis factor receptor
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
ATE446771T1 (de) * 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
WO2003014294A2 (en) 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
NZ570777A (en) 2002-05-17 2009-04-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT1631313E (pt) * 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
CA2618765A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule

Similar Documents

Publication Publication Date Title
JP2009537563A5 (enExample)
AU2019289200B2 (en) Bicyclic peptide ligands specific for Nectin-4
JP2007500236A5 (enExample)
Combe et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
JP2008538564A5 (enExample)
JP2010248199A5 (enExample)
KR102580378B1 (ko) 릴루졸의 설하 제제
JP2009539841A5 (enExample)
JP2011518179A5 (enExample)
JP2010529957A5 (enExample)
AU2015230986A1 (en) Cenicriviroc for the treatment of fibrosis
JP2017500018A5 (enExample)
JP2014506321A5 (enExample)
CA2568352A1 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
JP2014534956A5 (enExample)
JP2005535588A5 (enExample)
JP2005508338A5 (enExample)
JP2020535149A5 (enExample)
JP2006506942A5 (enExample)
JP2008521426A5 (enExample)
JP2015172060A5 (enExample)
JP2023521623A (ja) 過炎症性症候群の処置
JP2003531863A (ja) 非虚血状態での炎症関連疾患の治療法
Chave et al. Henoch‐Schönlein purpura following hepatitis B vaccination
JP2010514834A5 (enExample)